Research

Approximately 240 eligible adult participants (>=18 years old) who meet Diagnostic and Statistical Manual of Mental Disorders (DSM-5-TR) criteria for Major Depressive Disorder (MDD) will be enrolled. Participants will be randomly assigned to receive a single oral dose of Psilocybin 25 mg, Psilocybin 5 mg, or inactive placebo. The purpose of this study is to evaluate the efficacy, safety, and tolerability of Psiloc... Source record lists lead sponsor Usona Institute and overall status Active Not Recruiting.

Last verified: 2026-06-12

The goal of this clinical trial is to investigate treatment with psilocybin and psychotherapy for the treatment of people with Alcohol Use Disorder (AUD). The main question\[s\] it aims to answer are: * Does treatment with psilocybin and therapy help reduce alcohol consumption more than placebo and therapy? * Is treatment with psilocybin and therapy safe for participants? Participants will * Attend 13 study visits... Source record lists lead sponsor Clairvoyant Therapeutics and overall status Unknown.

Last verified: 2026-06-12

The aim of this study is to determine if a single dose of psilocybin administered with motivational enhancement therapy (MET) can reduce heavy drinking in patients with an alcohol use disorder (AUD). Source record lists lead sponsor University of Calgary and overall status Recruiting.

Last verified: 2026-06-12

ClinicalTrials.gov lists this University of Southern California study as recruiting. The study is titled Mindfulness-assisted Psychedelic Therapy and is located at USC's Brain and Creativity Institute.

Last verified: 2026-06-12

ClinicalTrials.gov lists this Stanford University study as not-yet-recruiting. The protocol studies psilocybin under EEG-controlled anesthesia conditions.

Last verified: 2026-06-12

UC Berkeley's Center for the Science of Psychedelics is an academic research center focused on psychedelic science for the public good. Its official site includes psilocybin education resources and a clinical-trials map, and ClinicalTrials.gov lists UC Berkeley psilocybin studies.

Last verified: 2026-06-12

UCSF Neuroscape has a Psychedelics Division focused on basic, translational, and clinical psychedelic science. Official UCSF pages identify Robin Carhart-Harris with studies involving psilocybin and other psychedelics, and ClinicalTrials.gov lists UCSF psilocybin protocols.

Last verified: 2026-06-12

Led by Robin Carhart-Harris (who developed the REBUS model of psychedelic action), UCSF's Psychedelics Division conducts neuroimaging and clinical research on psilocybin for depression, PTSD, and consciousness science. The UCSF/UC Berkeley joint PTSD trial enrolled veterans and first responders with significant Phase 2 results. Currently enrolling for multiple indications.

Last verified: 2026-05-21

The goal of this randomized placebo controlled trial is to compare the antidepressant effect of a single oral dose of psilocybin 25 mg compared to 1 mg in 100 patients with cancer related major depressive disorder. The main question it aims to answer is: The primary objective of this study is to evaluate the efficacy of a single 25 mg oral dose of psilocybin for major depressive disorder (MDD) compared to an activ... Source record lists lead sponsor Section for Affective Disorders; Northern Stockholm Psychiatry and overall status Recruiting.

Last verified: 2026-06-12

COMPASS Pathways is studying investigational COMP360 psilocybin treatment for treatment-resistant depression and other mental health indications. Its official materials describe COMP360 trials, and ClinicalTrials.gov lists COMPASS-sponsored psilocybin studies including NCT05624268.

Last verified: 2026-06-12

The Centre for Psychedelic Research at Imperial College London is the world's leading academic psychedelic research institution, directed by Robin Carhart-Harris. The center has produced more peer-reviewed psychedelic research publications than any other single institution, including foundational neuroimaging studies using fMRI and MEG, clinical trials for depression and end-of-life anxiety, and theoretical frameworks like the REBUS model of psychedelic action and the entropic brain hypothesis. Carhart-Harris and colleagues have fundamentally advanced understanding of both the neuroscience of the psychedelic state and its therapeutic applications.

Last verified: 2026-05-21

Imperial College London's Centre for Psychedelic Research studies the action of psychedelics in the brain and their clinical utility. The center is an academic research unit rather than a direct access provider.

Last verified: 2026-06-12

This randomized controlled clinical trial evaluates the effectiveness of psilocybin and psilocybin-assisted cognitive behavioral therapy (CBT) in the management of Major Depressive Disorder (MDD). The study aims to compare the effects of psilocybin-only therapy, CBT, and psilocybin-assisted CBT on depression symptoms, neurochemical markers, inflammatory markers, and neuroplasticity in individuals with MDD. Partici... Source record lists lead sponsor Khyber Medical University Peshawar and overall status Completed.

Last verified: 2026-06-12

Johns Hopkins Medicine operates a center focused on psychedelic and consciousness research, including studies of psilocybin. ClinicalTrials.gov lists multiple Johns Hopkins psilocybin studies, including PTSD, substance-use, depression, and healthy-volunteer protocols.

Last verified: 2026-06-12

ClinicalTrials.gov lists this Johns Hopkins University study as active-not-recruiting. The trial evaluates psilocybin for post-traumatic stress disorder at the Johns Hopkins Center for Psychedelic and Consciousness Research.

Last verified: 2026-06-12

This study aims to study the feasibility of psilocybin therapy for patients with Amyotropic Lateral Sclerosis (ALS) with depressed mood. The secondary objective is to assess its impact on depression, quality of life, hopelessness, and functional status in this patient population. Source record lists lead sponsor Johns Hopkins University and overall status Recruiting.

Last verified: 2026-06-12

The Boston Psychedelic Research Group at McLean Hospital (Harvard Medical School affiliate) is one of the most active academic psilocybin research programs on the East Coast. Led by Dr. Eli Kaplan (MD, PhD), the group runs FDA-registered clinical trials of psilocybin for treatment-resistant depression, OCD, and alcohol use disorder, with a particular focus on the neurobiological mechanisms underlying therapeutic response. McLean's research infrastructure — including neuroimaging facilities, an established inpatient psychiatric unit, and long-standing IRB relationships — enables trial designs that community-based research organizations cannot execute. Current enrolling trials include a psilocybin-for-OCD study replicating and extending the Moreno et al. 2006 work, and a mechanistic neuroimaging study examining DMN connectivity changes as predictors of therapeutic outcome. Massachusetts does not have a regulated psilocybin access program as of 2026. Ballot initiatives are in development; advocates expect a 2027 or 2028 vote. In the interim, clinical trial participation is the only legal psilocybin access pathway in the state. Trial participation is free for qualifying participants.

Last verified: 2026-05-21

The overall objective of this study is to assess the feasibility, safety and preliminary efficacy of psilocybin-assisted therapy to alleviate opioid-refractory pain in patients with advanced-cancer. The name of the study intervention used in this research study is: Psilocybin (a tryptamine derivative) Source record lists lead sponsor Yvan Beaussant, MD, MSci and overall status Recruiting.

Last verified: 2026-06-12

This study aims to determine the safety and preliminary efficacy of psilocybin-assisted psychotherapy in improving alcohol-related outcomes among adults with severe alcohol use disorder in a a double-blind, dose-comparison concurrent control, randomized trial. Participants will undergo structured psychotherapy and will be randomized to two psilocybin sessions to receive either a full dose (30mg or 40mg) or low dos... Source record lists lead sponsor Brigham and Women's Hospital and overall status Not Yet Recruiting.

Last verified: 2026-06-12

The University of Michigan's Michigan Psychedelic Center focuses on education, research, therapy, and community engagement related to psychedelics. The supplied Michigan dataset specifically notes U-M research recruiting volunteers for a psilocybin fibromyalgia study covered by Bridge Michigan. This page functions as the Michigan academic research listing rather than a commercial access provider.

Last verified: 2026-06-15

The Open Foundation is a Dutch nonprofit research organization dedicated to advancing scientific knowledge of psychedelic substances and their therapeutic applications. Based in Amsterdam, the Foundation funds and conducts research at Dutch universities, hosts the annual Interdisciplinary Conference on Psychedelic Research (ICPR) — one of Europe's largest gatherings of psychedelic researchers — and publishes the Journal of Psychedelic Studies. The Open Foundation's work is particularly significant in the European regulatory context: European approval pathways for psychedelic medicines (through the EMA rather than the FDA) require European data, and the Foundation's research program contributes directly to that evidence base. The ICPR conference has hosted presentations from leading global researchers including those from Johns Hopkins, Imperial College London, and MAPS, facilitating the international research collaboration that accelerates the field. The Foundation also operates public education programs on psychedelic science and policy for Dutch audiences, recognizing that public understanding shapes the political environment in which research occurs.

Last verified: 2026-05-21

NCT06796062 is a New Mexico psilocybin clinical-trial record for opioid use disorder in Albuquerque. It remains a recruiting research listing and sits alongside the state's broader SB 219 medical psilocybin rollout. This is not a general public provider page.

Last verified: 2026-06-15

The University of New Mexico GPAT study is a group psilocybin-assisted therapy study for PTSD recruiting veterans and first responders. The supplied notes list VCulkin@salud.unm.edu as the contact email and identify the study through UNM's psychedelic studies page. This is a research listing, not a general provider booking page.

Last verified: 2026-06-15

NYU Langone Health's Center for Psychedelic Medicine conducts translational psychedelic research from basic science through large-scale clinical trials. Its official research pages and ClinicalTrials.gov listings include psilocybin studies for alcohol use disorder, opioid use disorder, depression, and related conditions.

Last verified: 2026-06-12

ClinicalTrials.gov lists this Ohio State University Medical Center study as recruiting. The trial studies mindfulness-based psilocybin therapy for post-traumatic stress disorder.

Last verified: 2026-06-12

The purpose of this study is to see if psilocybin, an investigational drug, is safe and well tolerated. Researchers also want to know if psilocybin can improve symptoms of depression. This study will see if psilocybin is safe and well tolerated by tracking changes in suicidal thoughts and behaviour, monitoring if any participants choose to stop participating in the study, and measuring any serious side effects, as... Source record lists lead sponsor Brain and Cognition Discovery Foundation and overall status Completed.

Last verified: 2026-06-12

The goal of this neuroimaging clinical trial is to test whether psilocybin produces significant immediate changes in functional brain activity in networks associated with mood regulation and depression compared to placebo in patients with depression. The trial aims to determine if psilocybin: 1. Changes connectivity within brain networks associated with mood and depression 2. Changes blood flow in brain regions as... Source record lists lead sponsor Sunnybrook Health Sciences Centre and overall status Recruiting.

Last verified: 2026-06-12

Psilocybin, the chemical component of "magic mushrooms", has been administered with psychotherapy in several randomized clinical trials (RCTs) showing large and sustained antidepressant effects. There is interest to see if similar effects may be provided in those with obsessive compulsive disorder (OCD). The purpose of this study is to evaluate the safety, feasibility, and clinical effects of psilocybin administra... Source record lists lead sponsor Centre for Addiction and Mental Health and overall status Enrolling By Invitation.

Last verified: 2026-06-12

The purpose of this study is to see if one or two doses of psilocybin is more effective in relieving depressive symptoms in patients with treatment-resistant depression (TRD). Researchers also want to know if a second dose of psilocybin is safe and well-tolerated. This study will see if psilocybin is effective, safe, and well-tolerated by tracking changes in depressive symptoms, suicidality, and side effects. This... Source record lists lead sponsor University Health Network, Toronto and overall status Recruiting.

Last verified: 2026-06-12

About 30-50% of patients with advanced illness experience depression, anxiety, or decreased sense of purpose and autonomy. Together, these are called psychological distress. Treatment options such as medication and therapy are available; however, they do not always work and can be time-consuming and expensive. We need treatments that work well, quickly, and can be available to all patients with advanced illness wh... Source record lists lead sponsor Bruyère Health Research Institute. and overall status Recruiting.

Last verified: 2026-06-12

National University of Natural Medicine published Oregon-framework psilocybin research in August 2025 finding that psilocybin-assisted group therapy significantly reduced depression in low-income participants. The study is important because it used Oregon's legal services framework rather than an underground or purely clinical-trial setting. This is a research listing and not a provider booking page.

Last verified: 2026-06-15

To learn about the feasibility, safety, and effects of psilocybin-assisted psychotherapy on depression and/or anxiety in participants who are being treated for advanced cancer. Source record lists lead sponsor M.D. Anderson Cancer Center and overall status Recruiting.

Last verified: 2026-06-12

This study is assessing the efficacy and safety of NPX-5 in psilocybin-assisted psychotherapy for the treatment of adjustment disorder due to cancer diagnosis. Who is it for? This study is for people who are aged between 18 and 80 years old and suffer from anxiety after adjusting to an acutely stressful event of their cancer diagnosis. This is called adjustment disorder. Study details Participants in this study wi... Source record lists lead sponsor Psyence Australia Pty Ltd and overall status Recruiting.

Last verified: 2026-06-12

NCT05847686 is a University of Washington Phase I/II clinical trial testing psilocybin combined with therapy for patients with metastatic cancer and cancer-related anxiety or distress. The supplied Washington dataset identifies it as the UW psilocybin cancer-related distress trial. This is a research listing, not a commercial access program.

Last verified: 2026-06-15

NCT06853912, also referenced as PsiloStudy, is a University of Washington state-funded trial of psilocybin with psychological support for military veterans and first responders with co-occurring PTSD and alcohol use disorder. Source notes describe a single 25 mg psilocybin dose, non-directive psychological support, and integration therapy, with enrollment opening in early 2025. This is a research trial, not a public commercial service.

Last verified: 2026-06-15

The UW Center for Novel Therapeutics in Addiction Psychiatry is a University of Washington research program in the Department of Psychiatry and Behavioral Sciences directed by Dr. Nathan Sackett. Source notes describe PsiloStudy, a state-funded trial enrolling about 40 military veterans and first responders with co-occurring PTSD and alcohol use disorder for a single 25 mg psilocybin dose with psychological support and integration therapy. The center is also connected to group psilocybin-assisted therapy retreat research and Dr. Anthony Back's clinician-burnout psilocybin trial.

Last verified: 2026-06-15

Usona Institute is developing psilocybin as a potential treatment for major depressive disorder. Its official psilocybin page describes the uAspire Phase 3 study, and ClinicalTrials.gov lists NCT06308653 with Usona Institute as lead sponsor.

Last verified: 2026-06-12